Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 1/20 | 0.58 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.55 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.53 |
| ▸ | NPC1 | O15118 | 1/20 | 0.51 |
| ▸ | RAB9A | P51151 | 1/20 | 0.51 |
| ▸ | CA12 | O43570 | 1/20 | 0.49 |
| ▸ | CA1 | P00915 | 1/20 | 0.49 |
| ▸ | CA2 | P00918 | 1/20 | 0.49 |
| ▸ | CA7 | P43166 | 1/20 | 0.49 |
| ▸ | KIF11 | P52732 | 1/20 | 0.47 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.47 |
| ▸ | TGM2 | P21980 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5958669 | 0.85 | FFAR1 (0.44) | FFAR1EPHX2L3MBTL1NPC1RAB9A | |
| SCHEMBL13760549 | 0.84 | SMN1; SMN2 (0.56) | FFAR1 | |
| SCHEMBL5692310 | 0.83 | ALDH1A1 (0.44) | FFAR1NPC1RAB9ACA12CA1 | |
| SCHEMBL24279571 | 0.83 | KIF11 (0.54) | FFAR1EPHX2NPC1RAB9ACA12 | |
| SCHEMBL18282719 | 0.83 | EPHX2 (0.53) | FFAR1EPHX2L3MBTL1NPC1RAB9A | |
| SCHEMBL12156937 | 0.83 | FFAR1 (0.65) | FFAR1EPHX2L3MBTL1NPC1RAB9A | |
| Hydrochloric Acid SCHEMBL5773679 | 0.82 | POLB (0.49) | FFAR1EPHX2L3MBTL1NPC1RAB9A | |
| SCHEMBL19707556 | 0.81 | RAB9A (0.61) | FFAR1EPHX2L3MBTL1NPC1RAB9A | |
| SCHEMBL1441279 | 0.81 | LMNA (0.57) | ALDH1A1LMNA | |
| SCHEMBL130789 | 0.81 | SMN1; SMN2 (0.53) | EPHX2NPC1RAB9ACA12CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 191 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118910628-A | Selenizing and amination method of olefin under mild electrochemical condition | 湘潭大学 | 2024-11-08 | — | — | CN | claimed |
| CN-119219546-B | Halogenated fullerene pyrrolidine derivative, and preparation method and application thereof | XIAMEN UNIVERSITY (CN) | 2026-05-26 | — | — | CN | disclosed |
| WO-2025224599-A1 | PYRROLIDINE-BASED GLUCOSE-DEPENDENT INSULINOTROPIC POLYPEPTIDE RECEPTOR ANTAGONISTS AND USES THEREOF | PFIZER INC. (US) | 2025-10-30 | — | — | WO | disclosed |
| US-20250326741-A1 | GLUCOSE-DEPENDENT INSULINOTROPIC POLYPEPTIDE RECEPTOR ANTAGONISTS AND USES THEREOF | PFIZER INC. (US) | 2025-10-23 | — | — | US | disclosed |
| US-12268683-B2 | Compounds and methods for synergistic activation of M channels | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2025-04-08 | — | — | US | disclosed |
| CN-116554050-B | Amide phenol derivative and application thereof | 四川大学 | 2025-03-18 | — | — | CN | disclosed |
| CN-119219546-A | Halogenated fullerene pyrrolidine derivative, and preparation method and application thereof | 厦门大学 | 2024-12-31 | — | — | CN | disclosed |
| CN-118910628-A | Selenizing and amination method of olefin under mild electrochemical condition | 湘潭大学 | 2024-11-08 | — | — | CN | disclosed |
| WO-2024130161-A2 | NOVEL CAMPTOTHECIN DERIVATIVES AND CONJUGATES THEREOF | BIONECURE THERAPEUTICS INC (US) | 2024-06-20 | — | — | WO | disclosed |
| US-20240034753-A1 | THERAPEUTIC PEPTIDES | COHBAR, INC. | 2024-02-01 | — | — | US | disclosed |
| EP-1307214-A1 | HIGHLY HOMOGENEOUS MOLECULAR MARKERS FOR ELECTROPHORESIS | INVITROGEN CORPORATION (US) | 2003-05-07 | — | — | EP | disclosed |
| EP-1076563-A4 | DIPEPTIDE CASPASE INHIBITORS AND THE USE THEREOF | CYTOVIA INC (US) | 2003-04-23 | — | — | EP | disclosed |
| US-20020155455-A1 | Highly homogeneous molecular markers for electrophoresis | INVITROGEN CORPORATION | 2002-10-24 | — | — | US | disclosed |
| EP-1220869-A1 | CASPASE INHIBITORS FOR THE TREATMENT AND PREVENTION OF CHEMOTHERAPY AND RADIATION THERAPY INDUCED CELL DEATH | Cytovia, Inc. (US) | 2002-07-10 | — | — | EP | disclosed |
| WO-2002013848-A1 | HIGHLY HOMOGENEOUS MOLECULAR MARKERS FOR ELECTROPHORESIS | INVITROGEN CORPORATION (US) | 2002-02-21 | — | — | WO | disclosed |
| CN-1297354-A | Dipeptide caspase inhibitors and use thereof | CYTOVIA INC (US) | 2001-05-30 | — | — | CN | disclosed |
| WO-2001027140-A1 | CASPASE INHIBITORS FOR THE TREATMENT AND PREVENTION OF CHEMOTHERAPY AND RADIATION THERAPY INDUCED CELL DEATH | CYTOVIA, INC. (US) | 2001-04-19 | — | — | WO | disclosed |
| EP-1076563-A1 | DIPEPTIDE CASPASE INHIBITORS AND THE USE THEREOF | Cytovia, Inc. (US) | 2001-02-21 | — | — | EP | disclosed |
| US-6153591-A | PROTECTING NERVOUS SYSTEM FOLLOWING FOCAL ISCHEMIA AND GLOBAL ISCHEMIA; ALZHEIMER'S DISEASE, HUNTINGTON'S DISEASE, PRION DISEASES, PARKINSON'S DISEASE, MULTIPLE SCLEROSIS, AMYOTROPHIC LATERAL SCLEROSIS, ALOPACIA, RHEUMATOID ARTHRITIS | CYTOVIA, INC. (US) | 2000-11-28 | — | — | US | disclosed |
| WO-1999047154-A1 | DIPEPTIDE CASPASE INHIBITORS AND THE USE THEREOF | CYTOVIA, INC. (US) | 1999-09-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020155455-A1 | Highly homogeneous molecular markers for electrophoresis | CD44, HLA-C, HLA-A | FFAR1 4879/4885EPHX2 334/4885L3MBTL1 3795/4885 |
| US-20250326741-A1 | GLUCOSE-DEPENDENT INSULINOTROPIC POLYPEPTIDE RECEPTOR ANTAGONISTS AND USES THEREOF | GIPR, GLP1R, GPR119 | FFAR1 73/4885EPHX2 4731/4885L3MBTL1 1274/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.